SEC Form 4/A · accession 0001754540-18-000001
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Patrick J Crutcher
Officer — VP, Business Development
Period of report
Sep 25, 2018
Accepted (ET)
Oct 4, 2018 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 25, 2018 | A | 1,641,642 | — | A | 1,641,642 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Received in exchange for 1,000,000 shares of Ichorion Therapeutics, Inc. common stock in connection with the merger of Ichorion Therapeutics, Inc. into the Issuer. On September 25, 2018 the closing price of the Issuer's common stock was $4.55 per share.
Remarks
This Form 4 amendment is being filed to reflect the correct number of shares received in connection with the merger of Ichorion Therapeutics, Inc. into the Issuer.